RNS Number : 7927R
Kromek Group PLC
21 July 2025

21 July 2025

Kromek Group plc
("Kromek" or the "Group")

Kromek wins £1.7m contract under UK Government Framework
First contract award under the UK Government's Radiological Nuclear Detection Framework

Kromek (AIM: KMK), a global detection company delivering best-in-class solutions for the advanced imaging and CBRN detection markets, is pleased to announce that it has received its first contract, worth £1.7m, under the UK Government's Radiological Nuclear Detection Framework (the "Framework") for the procurement of radiological nuclear detection equipment and supporting services for the Home Office.

As noted in the Group's announcement of 23 September 2024, Kromek is pre-qualified to receive orders under three Framework categories,covering the supply of handheld, wearable and large volume static radiation detectors. The Group's new contract, which is part of the first procurement round under the four-year Framework, is for the supply of Kromek's D3S-ID wearable radiation detector and ongoing training and product maintenance. The total value for this contract is £1.7m, of which a significant majority is scheduled to be received in the Group's current financial year and which will contribute towards the expected revenue growth in the CBRN Detection segment.

Arnab Basu, CEO of Kromek, said: "We're proud to win our first contract under the UK Government framework for radiological and nuclear detection equipment. As one of the few pre-approved suppliers, we are uniquely positioned to support the Home Office's mission to strengthen national security and to secure further strategic orders. This contract affirms our leadership in the sector and highlights the significant growth potential unlocked by our selection for this critical framework".

Kromek Group plc
Arnab Basu, CEO +44 (0)1740 626 060
Claire Burgess, CFO

Cavendish Capital Markets Limited (Nominated Adviser and Broker)
Geoff Nash/Giles Balleny/Seamus Fricker - Corporate Finance +44 (0)20 7220 0500
Tim Redfern - ECM
Michael Johnson - Sales

Gracechurch Group (Financial PR)
Harry Chathli/Claire Norbury/Henry Gamble +44 (0)20 4582 3500

Kromek Group plc

Kromek Group plc is a leading developer of radiation detection and bio-detection technology solutions for the advanced imaging and CBRN detection segments. Headquartered in County Durham, UK, Kromek has manufacturing operations in the UK and US, delivering on the vision of enhancing the quality of life through innovative detection technology solutions.

The advanced imaging segment comprises the medical (including CT and SPECT), security and industrial markets. Kromek provides its OEM customers with detector components, based on its core cadmium zinc telluride (CZT) platform, to enable better detection of diseases such as cancer and Alzheimer's, contamination in industrial manufacture and explosives in aviation settings.

In CBRN detection, the Group provides nuclear radiation detection solutions to the global homeland defence and security market. Kromek's compact, handheld, high-performance radiation detectors, based on advanced scintillation and solid-state readout technology, are primarily used to protect critical infrastructure, events, personnel and urban environments from the threat of 'dirty bombs'.

The Group is also developing bio-security solutions in the CBRN detection segment. These consist of fully automated and autonomous systems to detect a wide range of airborne pathogens.

Kromek is listed on AIM, a market of the London Stock Exchange, under the trading symbol 'KMK'.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

CNTQBLFLEDLEBBE